# Manus Bio

**Canonical:** https://apis.io/providers/manus-bio/  
**Website:** https://www.manusbio.com/  
**APIs profiled:** 0

Manus Bio Inc. (trading as "Manus", the BioAlternatives Company) is a Cambridge, Massachusetts industrial biotechnology company founded in 2011 out of MIT by Dr. Aji Parayil and Dr. Greg Stephanopoulos. Manus engineers microbial cell factories and precision-fermentation processes so that complex molecules normally obtained through petrochemical synthesis, agricultural extraction, or animal husbandry can be produced by fermentation instead - what the company calls bioalternatives. Its commercialized products include the first U.S. commercial-scale monk fruit sweetener (produced at its Augusta, Georgia BioFacility), the Yume M stevia Reb M sweetener co-developed with Tate & Lyle, citrus-derived aroma ingredients (Nootkatone 70, Valencene 80, BioNootkatone) for Givaudan, and an artemisinin antimalarial program funded by HHS/ASPR. It sells scale-up services through its BioAccelerator and BioManufacturing programs (protein engineering, strain development, bioprocess development from 250 ml to 3,000 L, pilot-scale and biomanufacturing). In April 2025 Manus merged with genome-engineering company Inscripta, adding whole-genome editing technology and the MAD7 CRISPR nuclease licensing program; inscripta.com is now a redirect notice. Manus is a manufacturer of physical ingredients and a contract development and manufacturing organization - it sells molecules and services, not software. It publishes no public API, developer portal, SDK, webhook surface, or machine-readable specification of any kind, and its computational and AI-driven enzyme-engineering tools are internal capabilities that support its services rather than a customer-facing platform.

## Kin Score — 11.4 / 100 (minimal)

Scored 2026-08-17 under rubric 0.11.0. Trend: flat (+0.0 from 11.4).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Operational Transparency | 5.3 |
| Developer Ergonomics | 2.2 |
| Commercial Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Security (1)

- **Manus Bio Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Biotechnology, Synthetic Biology, Biomanufacturing, Industrial Biotechnology, Precision Fermentation, Ingredients, Food and Beverage, Sustainability, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/manus-bio/). Scores are computed from the provider's own public artifacts under a published rubric.